HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use NEVANAC® safely and effectively. See full prescribing information for NEVANAC.

NEVANAC (nepafenac ophthalmic suspension), 0.1%, for topical ophthalmic use
Initial U.S. Approval: 2005

-------------------------INDICATIONS AND USAGE--------------------------

NEVANAC (nepafenac ophthalmic suspension), 0.1% is a nonsteroidal, anti-inflammatory prodrug indicated for the treatment of pain and inflammation associated with cataract surgery (1).

------------------------DOSAGE AND ADMINISTRATION----------------------

One drop of NEVANAC (nepafenac ophthalmic suspension), 0.1% should be applied to the affected eye three-times-daily beginning 1 day prior to cataract surgery, continued on the day of surgery and through the first 2 weeks of the postoperative period. (2)

----------------------DOSAGE FORMS AND STRENGTHS---------------------

Sterile ophthalmic suspension: 0.1% (3)
3 mL in a 4 mL bottle.

------------------------------CONTRAINDICATIONS----------------------------

Hypersensitivity to any of the ingredients in the formula or to other NSAIDS. (4)

--------------------------WARNINGS AND PRECAUTIONS---------------------

Increased bleeding time due to interference with thrombocyte aggregation (5.1)
Delayed healing (5.2)
Corneal effects including keratitis (5.3)

----------------------------ADVERSE REACTIONS----------------------------

Most common adverse reactions (5 to 10%) are capsular opacity, decreased visual acuity, foreign body sensation, increased intraocular pressure and sticky sensation. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Alcon Laboratories, Inc. at 1-800-757-9195 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 12/2017
FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE
NEVANAC* (nepafenac ophthalmic suspension), 0.1% is indicated for the treatment of pain and inflammation associated with cataract surgery.

2 DOSAGE AND ADMINISTRATION
2.1 Recommended Dosing
One drop of NEVANAC (nepafenac ophthalmic suspension), 0.1% should be applied to the affected eye three-times-daily beginning 1 day prior to cataract surgery, continued on the day of surgery and through the first 2 weeks of the postoperative period. Shake the container well prior to dosing.

2.2 Use with Other Topical Ophthalmic Medications
NEVANAC (nepafenac ophthalmic suspension), 0.1% may be administered in conjunction with other topical ophthalmic medications such as beta-blockers, carbonic anhydrase inhibitors, alpha-agonists, cycloplegics, and mydriatics.

If more than one topical ophthalmic medication is being used, the medicines must be administered at least 5 minutes apart.

3 DOSAGE FORMS AND STRENGTHS
Sterile ophthalmic suspension 0.1%
3 mL in a 4 mL bottle

4 CONTRAINDICATIONS
NEVANAC (nepafenac ophthalmic suspension), 0.1% is contraindicated in patients with previously demonstrated hypersensitivity to any of the ingredients in the formula or to other non-steroidal anti-inflammatory drugs (NSAIDs).

5 WARNINGS AND PRECAUTIONS
5.1 Increased Bleeding Time
With some NSAIDs, including NEVANAC (nepafenac ophthalmic suspension), 0.1%, there exists the potential for increased bleeding time due to interference with thrombocyte aggregation. There have been reports that ocularly applied NSAIDs may cause increased bleeding of ocular tissues (including hyphema) in conjunction with ocular surgery.

It is recommended that NEVANAC (nepafenac ophthalmic suspension), 0.1% be used with caution in patients with known bleeding tendencies or who are receiving other medications which may prolong bleeding time.

5.2 Delayed Healing
Topical NSAIDs, including NEVANAC (nepafenac ophthalmic suspension), 0.1%, may slow or delay healing.
Topical corticosteroids are also known to slow or delay healing. Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems.

Reference ID: 4195615
5.3 Corneal Effects

Use of topical NSAIDs may result in keratitis. In some susceptible patients, continued use of topical NSAIDs may result in epithelial breakdown, corneal thinning, corneal erosion, corneal ulceration or corneal perforation. These events may be sight threatening. Patients with evidence of corneal epithelial breakdown should immediately discontinue use of topical NSAIDs, including NEVANAC (nepafenac ophthalmic suspension), 0.1%, and should be closely monitored for corneal health.

Postmarketing experience with topical NSAIDs suggests that patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (e.g., dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries within a short period of time may be at increased risk for corneal adverse events which may become sight threatening. Topical NSAIDs should be used with caution in these patients.

Postmarketing experience with topical NSAIDs also suggests that use more than 1 day prior to surgery or use beyond 14 days post-surgery may increase patient risk and severity of corneal adverse events.

5.4 Contact Lens Wear

NEVANAC (nepafenac ophthalmic suspension), 0.1% should not be administered while using contact lenses.

6 ADVERSE REACTIONS

The following adverse reactions are discussed in greater detail in other sections of labeling:

- Increased Bleeding Time [see Warnings and Precautions (5.1)]
- Delayed Healing [see Warnings and Precautions (5.2)]
- Corneal Effects [see Warnings and Precautions (5.3)]

6.1 Clinical Studies Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to the rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The most frequently reported ocular adverse reactions following cataract surgery were capsular opacity, decreased visual acuity, foreign body sensation, increased intraocular pressure, and sticky sensation. These reactions occurred in approximately 5 to 10% of patients.

Other ocular adverse reactions occurring at an incidence of approximately 1 to 5% included conjunctival edema, corneal edema, dry eye, lid margin crusting, ocular discomfort, ocular hyperemia, ocular pain, ocular pruritus, photophobia, tearing and vitreous detachment.

Some of these reactions may be the consequence of the cataract surgical procedure.

Non-ocular adverse reactions reported at an incidence of 1 to 4% included headache, hypertension, nausea/vomiting, and sinusitis.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Teratogenic Effects

Pregnancy Category C: Reproduction studies performed with nepafenac in rabbits and rats at oral doses up to 10 mg/kg/day have revealed no evidence of teratogenicity due to nepafenac, despite the induction of maternal toxicity. At this dose, the animal plasma exposure to nepafenac and amfenac was approximately 260 and 2400
times human plasma exposure at the recommended human topical ophthalmic dose for rats and 80 and 680 times human plasma exposure for rabbits, respectively. In rats, maternally toxic doses greater than or equal to 10 mg/kg were associated with dystocia, increased postimplantation loss, reduced fetal weights and growth, and reduced fetal survival.

Nepafenac has been shown to cross the placental barrier in rats. There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, NEVANAC *(nepafenac ophthalmic suspension), 0.1% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Non-teratogenic Effects
Because of the known effects of prostaglandin biosynthesis inhibiting drugs on the fetal cardiovascular system (closure of the ductus arteriosus), the use of NEVANAC (nepafenac ophthalmic suspension), 0.1% during late pregnancy should be avoided.

8.3 Nursing Mothers
Nepafenac is excreted in the milk of lactating rats. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when NEVANAC (nepafenac ophthalmic suspension), 0.1% ophthalmic suspension is administered to a nursing woman.

8.4 Pediatric Use
The safety and effectiveness of NEVANAC (nepafenac ophthalmic suspension), 0.1% in pediatric patients below the age of 10 years have not been established.

8.5 Geriatric Use
No overall differences in safety and effectiveness have been observed between elderly and younger patients.

11 DESCRIPTION
NEVANAC *(nepafenac ophthalmic suspension), 0.1% is a sterile, topical NSAID prodrug for ophthalmic use. Each mL of NEVANAC (nepafenac ophthalmic suspension), 0.1% contains 3 mg of nepafenac. Nepafenac is designated chemically as 2-amino-3-benzoylebenzeneacetamide with an empirical formula of C_{15}H_{14}N_{2}O_{2}. The structural formula of nepafenac is:

![Structural formula of nepafenac](image)

Nepafenac is a yellow crystalline powder. The molecular weight of nepafenac is 254.28. NEVANAC (nepafenac ophthalmic suspension), 0.1% is supplied as a sterile, aqueous suspension with a pH approximately of 7.4.

The osmolality of NEVANAC (nepafenac ophthalmic suspension), 0.1% is approximately 305 mOsm/kg. Each mL of NEVANAC (nepafenac ophthalmic suspension), 0.1% contains: Active: nepafenac 0.1% Inactives: boric acid, propylene glycol, carbomer 974P, sodium chloride, tyloxapol, edetate disodium, benzalkonium chloride 0.005% (preservative), sodium hydroxide and/or hydrochloric acid to adjust pH and purified water, USP.
12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

After topical ocular dosing, nepafenac penetrates the cornea and is converted by ocular tissue hydrolases to amfenac, an NSAID. Amfenac is thought to inhibit the action of prostaglandin H synthase (cyclooxygenase), an enzyme required for prostaglandin production.

12.3 Pharmacokinetics

Low but quantifiable plasma concentrations of nepafenac and amfenac were observed in the majority of subjects 2 and 3 hours post dose, respectively, following bilateral topical ocular 3 times-daily dosing of nepafenac ophthalmic suspension, 0.1%. The mean steady-state $C_{\text{max}}$ for nepafenac and for amfenac were $0.310 \pm 0.104$ ng/mL and $0.422 \pm 0.121$ ng/mL, respectively, following ocular administration.

Nepafenac at concentrations up to 300 ng/mL did not inhibit the in vitro metabolism of 6 specific marker substrates of cytochrome P450 (CYP) isozymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4). Therefore, drug-drug interactions involving CYP-mediated metabolism of concomitantly administered drugs are unlikely. Drug-drug interactions mediated by protein binding are also unlikely.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Nepafenac has not been evaluated in long-term carcinogenicity studies. Increased chromosomal aberrations were observed in Chinese hamster ovary cells exposed in vitro to nepafenac suspension. Nepafenac was not mutagenic in the Ames assay or in the mouse lymphoma forward mutation assay. Oral doses up to 5,000 mg/kg did not result in an increase in the formation of micronucleated polychromatic erythrocytes in vivo in the mouse micronucleus assay in the bone marrow of mice.

Nepafenac did not impair fertility when administered orally to male and female rats at 3 mg/kg (approximately 90 and 380 times the plasma exposure to the parent drug, nepafenac, and the active metabolite, amfenac, respectively, at the recommended human topical ophthalmic dose).

14 CLINICAL STUDIES

In 2 double-masked, randomized clinical trials in which patients were dosed 3 times-daily beginning 1 day prior to cataract surgery, continued on the day of surgery and for the first 2 weeks of the postoperative period, NEVANAC (nepafenac ophthalmic suspension), 0.1% demonstrated superior clinical efficacy compared to its vehicle in treating postoperative pain and inflammation.

Patients treated with NEVANAC* (nepafenac ophthalmic suspension), 0.1% were less likely to have ocular pain and measurable signs of inflammation (cells and flare) in the early postoperative period through the end of treatment than those treated with its vehicle.

For ocular pain in both studies, a significantly higher percentage of patients (approximately 80%) in the nepafenac group reported no ocular pain on the day following cataract surgery (Day 1) compared to those in the vehicle group (approximately 50%).

Results from clinical studies indicated that NEVANAC (nepafenac ophthalmic suspension) 0.1% has no significant effect upon intraocular pressure; however, changes in intraocular pressure may occur following cataract surgery.

Reference ID: 4195615
16 HOW SUPPLIED/STORAGE AND HANDLING

NEVANAC (nepafenac ophthalmic suspension), 0.1% is supplied in a white, oval, low density polyethylene DROP-TAINER® dispenser with a natural low density polyethylene dispensing plug and gray polypropylene cap presented in an overwrap (1.7 mL fill only). Tamper evidence is provided with a shrink band around the closure and neck area of the package.

3 mL in a 4 mL bottle………………………………………………………………………………………………NDC 0065-0002-03


17 PATIENT COUNSELING INFORMATION

Slow or Delayed Healing
Advising the patient of the possibility that slow or delayed healing may occur while using NSAIDs.

Avoiding Contamination of the Product
Advising the patient to avoid allowing the tip of the dispensing container to contact the eye or surrounding structures because this could cause the tip to become contaminated by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.

Use of the same bottle for both eyes is not recommended with topical eye drops that are used in association with surgery.

Contact Lens Wear
Advising the patient that NEVANAC (nepafenac ophthalmic suspension), 0.1% should not be administered while wearing contact lens.

Intercurrent Ocular Conditions
Advising the patient that if they develop an intercurrent ocular condition (e.g., trauma, or infection) or have ocular surgery, they should immediately seek their physician’s advice concerning the continued use of the multi-dose container.

Concomitant Topical Ocular Therapy
If more than one topical ophthalmic medication is being used, the medicines must be administered at least 5 minutes apart.

Shake Well Before Use
Advising the patient to shake the container well.

U.S. Patent Nos. 5,475,034 and 7,834,059.

ALCON®
A Novartis Company
Distributed by:
ALCON LABORATORIES, INC.
Fort Worth, Texas 76134 USA
*a trademark of Novartis
T201X - XX